Crizotinib Carries the Highest Thromboembolic Burden in ALK-Positive Lung Cancer

In ALK-positive non-small cell lung cancer, the choice of targeted therapy now appears to carry implications beyond tumor control. A systematic review and Bayesian network meta-analysis published in BMJ Open found that crizotinib was associated with a higher risk of total thromboembolism and venous thromboembolism than chemotherapy, alectinib, lorlatinib, brigatinib, and ceritinib. The signal was consistent enough to separate crizotinib from several other treatment options across eight randomized controlled trials.

The comparison matters because thrombosis is not a rare, abstract complication in advanced lung cancer. Patients already live with a baseline prothrombotic state driven by malignancy, immobility, inflammation, vascular injury, and frequent central venous access. A therapy that pushes risk further upward can alter hospitalization rates, anticoagulation decisions, and the timing of treatment interruptions. In practice, the drug used to suppress the driver mutation can also shape the patient’s vascular risk profile.

Network Meta-Analysis Draws a Clear Pattern Around Venous Events

Investigators searched PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, and Web of Science through 10 June 2023 and included published randomized controlled trials comparing chemotherapy with ALK tyrosine kinase inhibitors. Risk of bias was assessed with the Cochrane tool, and the network meta-analysis was run in R using GEMTC. Model fit was evaluated with deviation information criteria, convergence was monitored with Gelman-Rubin statistics and trace plots, and the surface under the cumulative ranking was used to estimate the relative probability of thromboembolic events across regimens. The analytic framework was designed to estimate indirect and direct treatment comparisons within a single coherent model.

Eight randomized trials formed the evidence base. Against crizotinib, chemotherapy lowered the odds of total thromboembolism with an odds ratio of 0.28 and 95% credible intervals from 0.11 to 0.63. Brigatinib also showed lower total thromboembolic risk, with an odds ratio of 0.31 and 95% credible intervals from 0.11 to 0.79, while ceritinib showed the lowest estimate in the network, with an odds ratio of 0.13 and 95% credible intervals from 0.03 to 0.45. The same direction held for venous thromboembolism: chemotherapy, brigatinib, and ceritinib all ranked below crizotinib for VTE occurrence.

Crizotinib stood out.

Why a thrombotic signal can emerge in targeted therapy

The biology is plausible even before a clinician opens the odds-ratio table. ALK-positive lung cancer itself is a thrombogenic disease, and treatment can either amplify or temper that risk depending on off-target vascular effects, treatment intensity, and disease control. More effective tumor suppression can reduce cancer-driven coagulation signaling, while drug-specific toxicities may influence endothelial function, platelet activation, liver metabolism of anticoagulants, or the need for treatment interruptions that leave the underlying hypercoagulable state unchecked. In a setting where the patient’s clotting system is already primed, small pharmacologic differences can become visible in event rates.

The meta-analysis did not find significant differences in arterial thromboembolism among the available treatment options. That separation between venous and arterial outcomes is clinically useful. Venous clotting in cancer often tracks more closely with inflammation, immobilization, venous stasis, and tumor-related coagulation pathways, whereas arterial events tend to reflect a broader mix of atherosclerotic disease, platelet biology, and conventional cardiovascular risk factors. The absence of a clear arterial signal suggests that the excess risk linked to crizotinib in this network is concentrated in the venous compartment rather than representing a generalized vascular toxicity pattern.

What the Ranking Means at the Bedside

For oncologists treating ALK-positive non-small cell lung cancer, the findings argue for more than a simple efficacy discussion. A patient with recent thrombosis, a strong family history of venous disease, prolonged immobility, or other clotting risks may warrant closer attention when crizotinib is being considered. The data do not mandate a one-size-fits-all switch, but they do support a drug-selection conversation that includes thromboembolic liability alongside response, central nervous system penetration, tolerability, and access.

Chemotherapy also ranked below crizotinib for total thromboembolism and VTE in this analysis, which reinforces the idea that the hazard is not merely a function of treating advanced cancer. Crizotinib appears to sit on the unfavorable side of the comparison network for clotting outcomes. In an evidence base that already includes multiple next-generation ALK inhibitors, this matters when selecting initial therapy or when revisiting treatment after progression.

The authors’ conclusion was direct: compared with chemotherapy, alectinib, lorlatinib, brigatinib, and ceritinib, crizotinib significantly increased the risk of thromboembolism and venous thromboembolism. Because the network relied on randomized trials rather than observational comparisons, the analysis offers a cleaner view of relative risk than retrospective series usually can. Still, the scope remains bounded by the trial populations, the available event reporting, and the fact that thromboembolism was not necessarily the primary endpoint in every study.

What this evidence does and does not settle

The study does not establish a single mechanism for the excess clotting seen with crizotinib. It also does not provide patient-level predictors, so the meta-analysis cannot identify which individuals are most vulnerable within the ALK-positive population. The analysis likewise cannot tell clinicians whether routine prophylactic anticoagulation would neutralize the difference, or whether the observed signal reflects a mixture of drug effect, exposure duration, and differences in trial ascertainment.

Even so, the practical message is hard to ignore: in ALK-positive non-small cell lung cancer, thromboembolism is not evenly distributed across targeted therapies. Crizotinib consistently occupied the less favorable position for venous and total thrombotic events, while several other ALK-directed approaches compared more favorably. For a disease in which long-term treatment selection increasingly shapes both survival and toxicity, clot risk is part of the therapeutic equation, not an afterthought.


Reporting by Dr. Revathy Mohan V.R., MBBS for Medicine World Foundation, with additional data provided by BMJ Open.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA